Overview

Vitamin D Basics

Therapeutic Focus

Product Candidates

 

Overview

Cytochroma has four product candidates targeting the CKD market. CTAP101 Capsules is targeted as a treatment for vitamin D insufficiency. CTA018 Injection and CTAP201 Injection are both targeted as treatments for SHPT and are intended to address different segments of the overall market. The phosphate management products target hyperphosphatemia with the goal of improving the control of SHPT.

pipeline

Last updated on July 2009
*MTPC will co-develop and co-commercialize CTA018 with Cytochroma in the U.S.,
and has an exclusive royalty-bearing license in Asia.